Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.
Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.
Aeschenvorstadt 48, 4051 Basel, Switzerland